Infectious Disease

The study participants will now receive the variant-specific COVID-19 vaccine from Moderna

March 31, 2021

1 min read

Source / information

Published by:

Disclosure:
Fauci does not report any relevant financial information.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact [email protected].

Back to Healio

The NIH announced on Wednesday the start of a Phase 1 clinical trial evaluating Moderna’s variant-specific COVID-19 vaccine. The shot was administered to the study participants.

Moderna last month shipped doses of the vaccine – a modified version of its mRNA 1273 vaccine, approved for use in the United States since December – to the NIH for testing. The vaccine has been optimized to target the B.1.351 variant, which was first identified in South Africa.

    Source: Adobe Stock

The NIH said a study has begun evaluating Moderna’s variant-specific COVID-19 vaccine. Source: Adobe Stock.

According to the NIH, the new study will include 210 healthy adults at four clinical research sites in Atlanta, Cincinnati, Nashville, and Seattle. Investigators at the four locations expect the study to be fully enrolled by the end of April, the NIH said.

The modified vaccine will be studied in both vaccinated and unvaccinated adults. The vaccinated adults received mRNA-1273 in a clinical study last year. You will be selected at random to receive either a single booster dose of 50 µg of the modified vaccine mRNA-1273.351 or a single dose of 25 µg of mRNA-1273 and a dose of 25 µg of mRNA-1273.351.

A separate clinical trial will evaluate a booster intake of the original vaccine in the remaining vaccinated study participants.

According to the director of the National Institute of Allergies and Infectious Diseases Anthony S. Fauci, MD, Variant B.1.351 has been found in at least nine US states. NIAID, which jointly developed the vaccine with Moderna, is leading and funding the new study.

Anthony S. Fauci

“Preliminary data shows that the COVID-19 vaccines currently available in the US should provide adequate protection against SARS-CoV-2 variants,” Fauci said in the NIH press release. “However, out of caution, NIAID has continued its partnership with Moderna to evaluate this variant vaccine candidate should an updated vaccine be required.”

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact [email protected].

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles